U.S. markets closed

Eledon Pharmaceuticals, Inc. (ELDN)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
6.90-0.14 (-1.99%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close7.04
Open7.04
Bid6.78 x 800
Ask7.25 x 800
Day's Range6.84 - 7.13
52 Week Range5.91 - 27.32
Volume84,886
Avg. Volume73,164
Market Cap98.716M
Beta (5Y Monthly)2.00
PE Ratio (TTM)N/A
EPS (TTM)-3.33
Earnings DateNov 15, 2021 - Nov 19, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est30.80
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Eledon Pharmaceuticals, Inc.
    Daily – Vickers Top Buyers & Sellers for 06/15/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    3 months agoArgus Research
View more
  • GlobeNewswire

    Eledon Pharmaceuticals to Present at Two Investor Conferences in September

    IRVINE, Calif., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for persons living with autoimmune disease, requiring an organ or cell-based transplant, or living with amyotrophic lateral sclerosis (ALS), today announced that management will present a corporate overview and participate in one-on-one investor meetings at the HC Wainwright 23rd Annual Global Investment Con

  • GlobeNewswire

    Eledon Pharmaceuticals Reports Second Quarter 2021 Operating and Financial Results

    Received approval from Health Canada to initiate a clinical trial of AT-1501 in kidney transplantation; company expects to initiate trial in Q4 with initial data in late 2022 Reached agreement with the FDA to conduct a preclinical renal transplant study evaluating AT-1501 monotherapy in four non-human primates; launched academic collaboration to conduct the study with data expected mid-2022 Announces plans to develop AT-1501 as a therapy for IgA nephropathy (IgAN), the fourth potential indicatio

  • GlobeNewswire

    Eledon Pharmaceuticals to Release Second Quarter Financial Results on Thursday, August 12, 2021

    Management to host conference call and webcast at 4:30 pm ETIRVINE, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing life-changing, targeted medicines for persons living with autoimmune disease, requiring an organ or cell-based transplant, or living with amyotrophic lateral sclerosis (ALS), today announced that it plans to release financial results for the second quarter ended June 30, 202